FENC
NASDAQFennec Pharmaceuticals Inc.
SectorHealth CareIndustryBiotechnology: Biological Products (No Diagnostic Substances)
Price$8.71+0.04 (+0.40%)
01:30 PM07:45 PM
News · 26 weeks700%
2025-12-142026-06-07
Mix4990d
- Insider25(51%)
- SEC Filings12(24%)
- Other8(16%)
- Earnings4(8%)
Latest news
25 items- INSIDERSEC Form 4 filed by Director Brughera Marco Maria4 - FENNEC PHARMACEUTICALS INC. (0001211583) (Issuer)
- INSIDERSEC Form 4 filed by Director Cook Jodi A4 - FENNEC PHARMACEUTICALS INC. (0001211583) (Issuer)
- INSIDERSEC Form 4 filed by Director Islam Khalid4 - FENNEC PHARMACEUTICALS INC. (0001211583) (Issuer)
- INSIDERSEC Form 4 filed by Director Rallis Chris A4 - FENNEC PHARMACEUTICALS INC. (0001211583) (Issuer)
- SECFennec Pharmaceuticals Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - FENNEC PHARMACEUTICALS INC. (0001211583) (Filer)
- PRFennec Announces Results of Annual MeetingRESEARCH TRIANGLE PARK, N.C., June 10, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (the "Company") (NASDAQ:FENC) (TSX:FRX) today announced that the nominees listed in the management proxy circular dated April 28, 2026 were elected as directors of the Company at the Annual General and Special Meeting of Shareholders held online on June 10, 2025. Detailed results of the vote for the election of directors are set out below: Name of NomineeVotes For% Votes ForVotes Withheld% Votes WithheldDr. Khalid Islam13,858,13197.84%304,7602.15%Mr. Chris A. Rallis13,808,79297.49%354,0992.50%Mr. Marco Brughera13,807,50197.49%355,3902.50%Dr. Jodi Cook13,259,89493.62%902,9976.37%Mr. Jeff Hackman13,4
- INSIDERDirector Raykov Rosty was granted 2,778 shares, exercised 15,597 shares at a strike of $2.45 and sold $93,766 worth of shares (9,747 units at $9.62) as part of a pre-agreed trading plan, increasing direct ownership by 7% to 130,079 units (SEC Form 4)4 - FENNEC PHARMACEUTICALS INC. (0001211583) (Issuer)
- INSIDERChief Strategy Officer Cioffi Christiana Marie was granted 156 shares, increasing direct ownership by 0.65% to 24,176 units (SEC Form 4)4 - FENNEC PHARMACEUTICALS INC. (0001211583) (Issuer)
- INSIDERChief Executive Officer Hackman Jeffrey S. was granted 1,159 shares, increasing direct ownership by 2% to 62,825 units (SEC Form 4)4 - FENNEC PHARMACEUTICALS INC. (0001211583) (Issuer)
- INSIDERCHIEF FINANCIAL OFFICER Andrade Robert was granted 1,703 shares, increasing direct ownership by 0.59% to 289,269 units (SEC Form 4)4 - FENNEC PHARMACEUTICALS INC. (0001211583) (Issuer)
- INSIDERChief Medical Officer Sayad Pierre Sargis was granted 168 shares, increasing direct ownership by 0.81% to 21,015 units (SEC Form 4)4 - FENNEC PHARMACEUTICALS INC. (0001211583) (Issuer)
- INSIDERChief Commercial Officer Evans Terry L was granted 168 shares, increasing direct ownership by 0.81% to 21,015 units (SEC Form 4)4 - FENNEC PHARMACEUTICALS INC. (0001211583) (Issuer)
- SECFennec Pharmaceuticals Inc. filed SEC Form 8-K: Other Events, Regulation FD Disclosure, Financial Statements and Exhibits8-K - FENNEC PHARMACEUTICALS INC. (0001211583) (Filer)
- PRFennec Pharmaceuticals Announces New Research Supporting Integration and Use of PEDMARK® at the 2026 ASCO Annual Meeting~ Growing Independent Research Efforts are Expanding Evidence Base Around How PEDMARK® (sodium thiosulfate injection) May Benefit Broader and More Diverse Patient Populations ~ ~ Real-World Evidence Shows Administration of PEDMARK® Approximately Six Hours After Cisplatin Can Be Safe & Easily Integrated into Patient Care and Does Not Compromise Cisplatin's Established Antitumor Activity ~ RESEARCH TRIANGLE PARK, N.C., May 21, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC, TSX:FRX), a specialty pharmaceutical company, today announced that new research evaluating PEDMARK® (sodium thiosulfate injection) across multiple patient populations and tumor types will be shared as
- SECFennec Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits8-K - FENNEC PHARMACEUTICALS INC. (0001211583) (Filer)
- PRFennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)RESEARCH TRIANGLE PARK, N.C., May 18, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) ("Fennec" or the "Company"), a specialty pharmaceutical company, today announced that on May 11, 2026, the Compensation Committee of the Company's Board of Directors approved the grant of stock option awards ("Stock Options") to purchase an aggregate of 50,000 of the Company's common shares to three new non-executive employees of the Company with a grant date of May 18, 2026 under the Company's 2026 Equity Inducement Plan (the "Inducement Plan"). The Stock Options consist of incentive stock options to purchase an aggregate of 49,141 shares and nonqualified stock options to pur
- SECSEC Form 10-Q filed by Fennec Pharmaceuticals Inc.10-Q - FENNEC PHARMACEUTICALS INC. (0001211583) (Filer)
- PRFennec Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update~ Achieved First Quarter 2026 Total Net Revenues of $15.1 Million, Up 73% Year Over Year ~ ~ Field Sales Expansion Showing Early Signs of Positive Results with Record PEDMARK® Demand in April 2026 ~ ~ Initiated Third Institution-Led Clinical Study Evaluating PEDMARK® in Adolescent and Young Adult (AYA) and Adult Patients with Head and Neck and Testicular Cancers ~ ~ Four Abstracts Evaluating PEDMARK® will be Included in the Upcoming 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Program ~ ~ Management to Host Conference Call Today at 8:30 a.m. ET ~ RESEARCH TRIANGLE PARK, N.C., May 14, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC, TSX:FRX), a sp
- INSIDERDirector Rallis Chris A exercised 14,344 shares at a strike of $2.44 and sold $58,756 worth of shares (8,346 units at $7.04) as part of a pre-agreed trading plan, increasing direct ownership by 11% to 63,077 units (SEC Form 4)4 - FENNEC PHARMACEUTICALS INC. (0001211583) (Issuer)
- SECSEC Form 144 filed by Fennec Pharmaceuticals Inc.144 - FENNEC PHARMACEUTICALS INC. (0001211583) (Subject)
- PRFennec Pharmaceuticals to Report First Quarter 2026 Financial Results on May 14, 2026RESEARCH TRIANGLE PARK, N.C., May 07, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC, TSX:FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its first quarter 2026 financial results before the opening of the U.S. financial markets on Thursday, May 14, 2026. Management will host a conference call and webcast that day to discuss the Company's financial and business results. Conference Call & Webcast Detail: Date: Thursday, May 14, 2026Time: 8:30 a.m. Eastern TimeWebcast Link: https://edge.media-server.com/mmc/p/2iptdco4Participant Link: https://register-conf.media-server.com/register/BIaa4b518aeb974d02873eccf8f56d92f3
- INSIDERDirector Raykov Rosty exercised 18,376 shares at a strike of $2.08 and sold $69,753 worth of shares (10,781 units at $6.47) as part of a pre-agreed trading plan, increasing direct ownership by 7% to 121,451 units (SEC Form 4)4 - FENNEC PHARMACEUTICALS INC. (0001211583) (Issuer)
- INSIDERChief Strategy Officer Cioffi Christiana Marie converted options into 155 shares, increasing direct ownership by 0.65% to 24,020 units (SEC Form 4)4 - FENNEC PHARMACEUTICALS INC. (0001211583) (Issuer)
- INSIDERChief Commercial Officer Evans Terry L converted options into 168 shares, increasing direct ownership by 0.81% to 20,847 units (SEC Form 4)4 - FENNEC PHARMACEUTICALS INC. (0001211583) (Issuer)
- INSIDERChief Medical Officer Sayad Pierre Sargis converted options into 168 shares, increasing direct ownership by 0.81% to 20,847 units (SEC Form 4)4 - FENNEC PHARMACEUTICALS INC. (0001211583) (Issuer)
FENC FAQ
6 questionsWhat does Fennec Pharmaceuticals Inc. do?
Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product PEDMARK, a formulation of Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.Where does FENC stock trade?
Fennec Pharmaceuticals Inc. (FENC) is listed on NASDAQ.What sector and industry is FENC in?
Fennec Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.What are analysts saying about FENC?
Fennec Pharmaceuticals Inc. has had 5 recent analyst actions on file. The most recent action was from B. Riley Securities: Buy with a $1600.00 price target on 2026-02-12. Recent price targets range from $1100.00 to $1600.00.What companies are similar to FENC?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare FENC side-by-side with any of them on Quantisnow.How can I track FENC on Quantisnow?
Quantisnow aggregates Fennec Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow FENC to receive live email and push alerts on every new disclosure.